Iovance Biotherapeutics's market cap is currently $1.69B. The company's EPS TTM is $-1.495; its P/E ratio is ―; Iovance Biotherapeutics is scheduled to report earnings on February 26, 2025, and the estimated EPS forecast is $-0.27. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 1.19M	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ -9.57M	$ -21.14M	$ -13.98M	$ -8.71M	$ -8.12M
Operating Income	$ -460.56M	$ -398.88M	$ -342.70M	$ -261.94M	$ -206.87M
EBITDA	$ -427.43M	$ -374.76M	$ -328.27M	$ -250.87M	$ -189.43M
Net Income	$ -444.04M	$ -389.92M	$ -327.82M	$ -257.23M	$ -187.07M
Balance Sheet
Cash & Short-Term Investments	$ 279.87M	$ 471.85M	$ 596.00M	$ 629.44M	$ 307.08M
Total Assets	$ 780.35M	$ 663.98M	$ 777.33M	$ 768.46M	$ 344.65M
Total Debt	$ 75.86M	$ 84.45M	$ 71.53M	$ 51.66M	$ 11.50M
Net Debt	$ -39.03M	$ -147.28M	$ -6.70M	$ -15.67M	$ -2.47M
Total Liabilities	$ 195.74M	$ 164.34M	$ 155.67M	$ 111.96M	$ 45.68M
Stockholders' Equity	$ 584.61M	$ 499.64M	$ 621.66M	$ 656.50M	$ 298.97M
Cash Flow
Free Cash Flow	$ -384.11M	$ -313.18M	$ -265.51M	$ -251.93M	$ -165.81M
Operating Cash Flow	$ -361.82M	$ -292.76M	$ -227.94M	$ -205.13M	$ -158.89M
Investing Cash Flow	$ -155.24M	$ 256.45M	$ 132.00K	$ -317.85M	$ 90.03M
Financing Cash Flow	$ 462.96M	$ 190.15M	$ 239.27M	$ 576.42M	$ 6.13M

Currency in USD

Iovance Biotherapeutics Earnings and Revenue History

Income Statement >

Iovance Biotherapeutics Debt to Assets

Balance Sheet >

Iovance Biotherapeutics Cash Flow

Cash Flow >

Iovance Biotherapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing